Evidence map›Paper›PMID 20218920›Full record

ReviewExpert opinion on biological therapy2010

Potential therapeutic applications of muscle-derived mesenchymal stem and progenitor cells.

Wesley M Jackson, Leon J Nesti, Rocky S Tuan

Abstract readReview
In one paragraph

Review in Expert opinion on biological therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Mesenchymal Stem Cells in Cancer Therapy.Advances in experimental medicine and biology · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Wesley M JacksonUniversity of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering, Department of Orthopaedic Surgery, 450 Technology Drive, Room 221, Pittsburgh, PA 15232, USA.
Leon J Nesti
Rocky S Tuan
National Institutes of Health · USUniversity of Pittsburgh · USWalter Reed Army Institute of Research · US

Funding

Cell and Molecular Biology of Skeletal DevelopmentZ01AR041131 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI TUAN, ROCKY S · 2002 to 2008
$6.0M
Pathogenesis of heterotopic ossificationZIAAR041191 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI NESTI, LEON · 2010 to 2014
$3.7M
ETHANOL, PTH, TGF-BETA 1, AND OSSEOINTEGRATIONF30AA005516 · NIAAA · THOMAS JEFFERSON UNIVERSITY · PI NESTI, LEON J · 1998 to 2000
$27k
Intramural NIH HHS Z01 AR041131NIAAA NIH HHS F30 AA005516
6 · The paper itself

Abstract

importance of the fieldMesenchymal adult stem cells have properties that make them attractive for use in tissue engineering and regenerative medicine. They are inherently plastic, enabling them to differentiate along different lineages, and promote wound healing and regeneration of surrounding tissues by modulating immune and inflammatory responses, promoting angiogenesis and secreting other trophic factors. Unlike embryonic stem cells, clinical uses of mesenchymal stem cells are not encumbered by ethical considerations or legal restrictions. AREAS COVERED IN THIS REVIEW: We discuss skeletal muscle as a source of mesenchymal stem and progenitor cells by reviewing their biology and current applications in tissue engineering and regenerative medicine. This paper covers literature from the last 5 - 10 years. WHAT THE READER WILL GAIN: Skeletal muscle is a plentiful source of mesenchymal stem and progenitor cells. This tissue may be obtained via routine biopsy or collection after surgical debridement. We describe the biology of these cells and provide an overview of therapeutic applications currently being developed to take advantage of their regenerative properties. TAKE HOME MESSAGE: There is potential for stem and progenitor cells derived from skeletal muscle to be incorporated in clinical interventions, either as a cellular therapy to modify the natural history of disease or as a component of engineered tissue constructs that can replace diseased or damaged tissues.

Indexed as

AdultHumansMesenchymal Stem CellsMuscle, SkeletalRegeneration

Identifiers

PMID20218920
PMCPMC3018682
OpenAlexW2031613531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.